Hassa, Nazwan
Unknown Affiliation

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

PERBEDAAN KUALITAS HIDUP BERDASARKAN SHORT FORM-36 ANTARA PENDERITA STROKE ISKEMIK SERANGAN PERTAMA DENGAN KEDUA Hassa, Nazwan; Hartono, Jimmy Eko Budi; Pudjonarko, Dwi
Majalah Kedokteran Neurosains Perhimpunan Dokter Spesialis Saraf Indonesia Vol 35 No 1 (2018)
Publisher : PERDOSNI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52386/neurona.v35i1.44

Abstract

  DIFFERENCES QUALITY OF LIFE BASED ON SHORT FORM–36 BETWEEN FIRST AND SECOND ATTACK ISCHEMIC STROKE PATIENTSABSTRACTIntroduction: Stroke is the biggest cause of physical disability, emotional, and social life in adults. The recurrent stroke let to decreased the quality of life.Aims: To know whether there is a difference in quality of life based on the Short Form-36 (SF-36) between first and second attack ischemic stroke patients.Methods: Observational analytic with retrospective cross sectional study in Neurology Polyclinic Dr. Kariadi Hospital, Semarang form July-September 2016. Inclusion criteria are patients with first or second attack of ischemic stroke, level education at least elementary school, age between 50-70 years old, and last attack 4 week or less before the sampling conducted. Quality of life were scored based on SF-36 between first and second attack patients. T-test and Mann- Whitney were used to analyze the data.Results: Fifty subject (25 in each group) included with mean age 57.72 (51-65) and 60.24 (51-70) years old in first attack and second attack group respectively. Older age showed lower quality of life score. The quality of life score is lower in older, stroke onset >1 year, and lower education. There was significant quality of life score difference between first and second attack group. Quality of life patients with first attack is better significantly compared to the second attack group in functional and physical domain, energy, and total score.Discussion: There is a significant difference in quality of life based on the SF-36 between first and second attack ischemic stroke patients.Keywords: Ischemic stroke, quality of  life, SF-36ABSTRAKPendahuluan: Stroke merupakan penyebab terbesar ketidakmampuan fisik, emosi, dan kehidupan sosial pada orang dewasa. Serangan stroke berulang menyebabkan peningkatan risiko penurunan kualitas hidup.Tujuan: Mengetahui perbedaan kualitas hidup pasien stroke iskemik serangan pertama dan kedua berdasarkan Short Form-36 (SF-36).Metode: Penelitian analitik observasional secara potong lintang retrospektif di Poliklinik Neurologi RSUP Dr. Kariadi, Semarang pada bulan Juli-September 2016. Kriteria inklusi adalah pasien stroke iskemik serangan pertama atau kedua, berpendidikan minimal SD atau sederajat, berusia antara 50-70 tahun, dan mengalami serangan stroke terakhir minimal 4 minggu sebelum penelitian. Dilakukan penilaian skor kualitas hidup berdasarkan SF–36 antara pasien stroke iskemik serangan pertama dengan kedua. Analisis menggunakan uji T-tes dan Mann-Whitney.Hasil: Terdapat 50 subjek yang terdiri dari masing-masing 25 subjek pada kelompok dengan stroke iskemik serangan pertama dan kelompok dengan serangan kedua dengan rerata usia 57,72 (51–65) tahun dan 60,24 (51–70) tahun. Usia yang semakin meningkat menunjukkan skor kualitas hidup semakin menurun. Skor kualitas hidup lebih rendah pada usia yang lebih tinggi, lama menderita stroke >1 tahun, dan pendidikan yang lebih rendah. Didapatkan perbedaan bermakna antara rerata skor kualitas hidup pasien stroke serangan pertama dan kedua. Kualitas hidup subjek pada serangan stroke pertama lebih baik secara bermakna dibandingkan pada kelompok serangan kedua, dalam domain fungsi dan peranan fisik, energi, serta total skor secara keseluruhan.Diskusi: Terdapat perbedaan bermakna kualitas hidup berdasarkan SF-36 antara pasien stroke iskemik serangan pertama dengan kedua.Kata kunci: SF-36, skor kualitas hidup, stroke iskemik
RIVASTIGMINE TRANSDERMAL PATCH FOR ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW Baskoro, Firza Yoga; Hassa, Nazwan; Hajar, Nabil; Balqis, Indira Aura
Journal of Pain, Headache and Vertigo Vol. 6 No. 2 (2025): September
Publisher : PERDOSNI (Perhimpunan Dokter Spesialis Neurologi Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/

Abstract

Background: Alzheimer's disease (AD) is the most common type of dementia disease. Acetylcholinesterase inhibitors (AChE-I) plays a pivotal role by increasing acetylcholine levels in the brain to improve cognitive function of Alzheimer's patients. Several agents including cholinesterase inhibitors such as donepezil and galantamine, as well as the NMDA receptor antagonist memantine are known for its benefit in increasing acetylcoline . However, Rivastigmin is the only AChE-I agent available in patch preparation. Objective : This study aims to evaluate the efficacy of Rivastigmin patch in improving cognitive function using the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) in Alzheimer's disease patients. Methods: This research was conducted in accordance with the Systematic Review without Meta-Analysis (SWiM) guideline. A systematic database search was conducted in Medline, Google Scholar, and Cochrane Central Libraries using a pre-determined search query. Articles were screened by independent reviewers for eligibility to be included in the study. After risk of bias was conducted, seven studies were included for this research. Results: The included studies reported varied outcomes regarding cognitive improvement in Alzheimer's disease (AD) patients, depending on the dosage of Rivastigmine used. Overall, Rivastigmine was found to slow the progression of cognitive decline, as measured by the ADAS-Cog, and in some cases, even reduced ADAS-Cog scores by up to 3 points . Rivastigmine patch is known to inhibit the action of acetylcholinesterase enzyme which causes degradation of acetylcholine in the synapse gap, ultimately improving the cognitive of AD patients. Studies also mention that Rivasitgmine patch preparation has better tolerance to side effects compared to capsules or placebo. Conclusion: Rivastigmine patch shows improvement of cognitive status in Alzheimer's patients and has good tolerability compared to placebo or capsule preparations. the long-term efficacy and safety of the rivastigmine patch remain underexplored, and the generalizability of the findings to diverse patient populations is uncertain.